Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease
Karsten Wicke, Andreas Haupt, Anton Bespalov
Expert Opinion on Investigational Drugs (2015) Vol. 24, Iss. 12, pp. 1515-1528
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status
Hilda Ferrero, Maite Solas, Paul T. Francis, et al.
CNS Drugs (2016) Vol. 31, Iss. 1, pp. 19-32
Closed Access | Times Cited: 92
Precision pharmacology for Alzheimer’s disease
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
Pharmacological Research (2018) Vol. 130, pp. 331-365
Open Access | Times Cited: 91
First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease
Patryk Pyka, Wawrzyniec Haberek, Małgorzata Więcek, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1580-1610
Open Access | Times Cited: 12
Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer’s disease by regulating cilia function
Lili Hu, Bingjie Wang, Yan Zhang
Alzheimer s Research & Therapy (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 81
Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT6 Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimer’s Disease
Katarzyna Grychowska, Grzegorz Satała, Tomasz Kos, et al.
ACS Chemical Neuroscience (2016) Vol. 7, Iss. 7, pp. 972-983
Open Access | Times Cited: 77
Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): recent advances
Samima Khatun, Abhinav Singh, Ghulam Nabi Bader, et al.
Journal of Biomolecular Structure and Dynamics (2021) Vol. 40, Iss. 24, pp. 14279-14302
Closed Access | Times Cited: 36
Novel non-sulfonamide 5-HT 6 receptor partial inverse agonist in a group of imidazo[4,5- b ]pyridines with cognition enhancing properties
David Vanda, Miroslav Soural, Vittorio Canale, et al.
European Journal of Medicinal Chemistry (2017) Vol. 144, pp. 716-729
Closed Access | Times Cited: 44
N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties
Paweł Zajdel, Krzysztof Marciniec, Grzegorz Satała, et al.
ACS Medicinal Chemistry Letters (2016) Vol. 7, Iss. 6, pp. 618-622
Open Access | Times Cited: 43
Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
Ramakrishna Nirogi, Anil Shinde, Rama Sastry Kambhampati, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 5, pp. 1843-1859
Closed Access | Times Cited: 42
Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets
Ayesha Khan, Anne Corbett, Clive Ballard
Expert Review of Neurotherapeutics (2017) Vol. 17, Iss. 7, pp. 683-695
Closed Access | Times Cited: 39
Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs
Mark J. Millan, Anne Dekeyne, Alain P. Gobert, et al.
Neuropharmacology (2020) Vol. 177, pp. 108099-108099
Open Access | Times Cited: 30
5‐HT6R null mutatrion induces synaptic and cognitive defects
Zehui Sun, Bingjie Wang, Chen Chen, et al.
Aging Cell (2021) Vol. 20, Iss. 6
Open Access | Times Cited: 25
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
Ramakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Behavioural Pharmacology (2018) Vol. 30, Iss. 1, pp. 16-35
Closed Access | Times Cited: 32
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity
Adam Bucki, Monika Marcinkowska, Joanna Śniecikowska, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 17, pp. 7483-7501
Closed Access | Times Cited: 29
Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6
Wesam Ali, Małgorzata Więcek, Dorota Łażewska, et al.
European Journal of Medicinal Chemistry (2019) Vol. 178, pp. 740-751
Closed Access | Times Cited: 24
Effects of the 5-HT 6 receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex
Arne Mørk, Rasmus Vinther Russell, Inge E.M. de Jong, et al.
European Journal of Pharmacology (2017) Vol. 799, pp. 1-6
Closed Access | Times Cited: 23
Synthesis, molecular docking and biological evaluation of 2-(thiophen-2-yl)-1H-indoles as potent HIV-1 non-nucleoside reverse transcriptase inhibitors
Marwa El‐Hussieny, Naglaa F. El‐Sayed, Ewies F. Ewies, et al.
Bioorganic Chemistry (2019) Vol. 95, pp. 103521-103521
Closed Access | Times Cited: 22
Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo
Sylwia Sudoł, Katarzyna Kucwaj‐Brysz, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112529-112529
Open Access | Times Cited: 19
Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets
István Gyertyán
Trends in Pharmacological Sciences (2016) Vol. 38, Iss. 2, pp. 113-126
Open Access | Times Cited: 18
Frameworking memory and serotonergic markers
Alfredo Meneses
Reviews in the Neurosciences (2017) Vol. 28, Iss. 5, pp. 455-497
Closed Access | Times Cited: 18
Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia
Radosław Magierski, Tomasz Sobów
Expert Review of Neurotherapeutics (2016) Vol. 16, Iss. 4, pp. 375-387
Closed Access | Times Cited: 17
Facts, Results, and Perspectives of the Current Alzheimer’s Disease Research
José Marco‐Contelles
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 3, pp. 1127-1128
Closed Access | Times Cited: 16
Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT6 receptor interaction
Battistina Asproni, Marco Catto, Giovanni Loriga, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 84, pp. 117256-117256
Open Access | Times Cited: 5
Pyrroloquinoline scaffold-based 5-HT6R ligands: Synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in the scaffold on affinity
Katarzyna Grychowska, Rafał Kurczab, Paweł Śliwa, et al.
Bioorganic & Medicinal Chemistry (2018) Vol. 26, Iss. 12, pp. 3588-3595
Closed Access | Times Cited: 16
The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases
Sylwia Sudoł, Agnieszka Cios, Magdalena Jastrzębska‐Więsek, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10773-10773
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top